- Home
- IOBT vs AVTX Comparison
IOBT vs AVTX Comparison
Compare IOBT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IOBT | AVTX |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7M | 339.9M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IOBT | AVTX |
|---|---|---|
| Price | $0.19 | $13.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $2.25 | ★ $32.57 |
| AVG Volume (30 Days) | ★ 1.3M | 592.2K |
| Earning Date | 05-13-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.77 | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $0.14 | $3.39 |
| 52 Week High | $2.79 | $20.72 |
Technical Indicators
Market Signals| Indicator | IOBT | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.67 | 32.77 |
| Support Level | $0.14 | $8.87 |
| Resistance Level | $0.40 | $16.40 |
| Average True Range (ATR) | 0.03 | 1.01 |
| MACD | -0.00 | -0.47 |
| Stochastic Oscillator | 22.76 | 3.28 |
Price Performance
Historical ComparisonAbout IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).